How well do randomized controlled trial data generalize to 'real-world' clinical practice settings? A comparison of two generalized anxiety disorder studies

European Neuropsychopharmacology

Volumn 24, Issue 1, 2014, Pages 125-132

  Kasper, Siegfried ^a   Brasser, Matthias ^b   Schweizer, Edward ^c   Lyndon, Gavin ^d   Prieto, Rita ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b PFIZER INC   (United States)

^c Paladin Consulting Group   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Generalized anxiety disorder; Hospital Anxiety and Depression Scale; Pregabalin; Randomized controlled trial

Indexed keywords

PLACEBO; PREGABALIN; VENLAFAXINE;

ADULT; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENERALIZED ANXIETY DISORDER; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL OUTCOMES STUDY SLEEP PROBLEMS INDEX; MIDDLE AGED; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; OPEN STUDY; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TREATMENT DURATION; TREATMENT OUTCOME; VERTIGO; VISUAL ANALOG SCALE; XEROSTOMIA;

GENERALIZED ANXIETY DISORDER; HOSPITAL ANXIETY AND DEPRESSION SCALE; PREGABALIN; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; ANALGESICS; ANXIETY DISORDERS; DOUBLE-BLIND METHOD; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; PAIN MEASUREMENT; PHYSICIAN'S PRACTICE PATTERNS; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84892479220     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2013.10.015     Document Type: Article

References (29)

1. Bandelow B., et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J. Biol. Psychiatry 2008, 9:248-312.
2. Bech P. Dose-response relationship of pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebo-controlled trials. Pharmacopsychiatry 2007, 40:163-168.
3. Cegedim Strategic Data, 2011. Pregabalin Patient Data MAT Q2.
4. Citrome L. Show me the evidence: using number needed to treat. South. Med. J. 2007, 100:881-884.
5. Feltner D., et al. Long-term efficacy of pregabalin in generalized anxiety disorder. Int. Clin. Psychopharmacol. 2008, 23:18-28.
6. Feltner D.E., et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J. Clin. Psychopharmacol. 2003, 23:240-249.
7. Flather M., Delahunty N., Collinson J. Generalizing results of randomized trials to clinical practice: reliability and cautions. Clin. Trials 2006, 3:508-512.
8. Guy, W., 1976. National Institute of Mental Health - Psychopharmacology Research Branch. Early Clinical Drug Evaluation Program. ECDEU Assessment Manual for Psychopharmacology. U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration. National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville, MD.
9. Hays R.D., et al. Psychometric properties of the Medical Outcomes Study Sleep measure. Sleep Med. 2005, 6:41-44.
10. Herrmann C., Buss U. Vorstellung und Validierung einer deutschen Version der "Hospital Anxiety and Depression Scale" (HAD-Skala); Ein Fragebogen zur Erfassung des psychischen Befindens bei Patienten mit korperlichen Beschwerden. Diagnostica (Berlin) 1994, 40:143-154.
11. Hidalgo R.B., Tupler L.A., Davidson J.R. An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J. Psychopharmacol. 2007, 21:864-872.
12. Kasper S., et al. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int. Clin. Psychopharmacol. 2009, 24:87-96.
13. Khan A., et al. Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports. Neuropsychopharmacology 2003, 28:552-557.
14. Khan A., et al. Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. Am. J. Psychiatry 2004, 161:2045-2049.
15. Lydiard R.B., et al. From the bench to the trench: a comparison of sertraline treatment of major depression in clinical and research patient samples. Prim. Care Companion J. Clin Psychiatry 1999, 1:154-162.
16. Möller H.-J., et al. Efficacy and tolerability of pregabalin in patients with generalized anxiety disorders in everyday clinical practice. Psychopharmakotherapie 2009, 6:211-217.
17. Montgomery S., et al. Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br. J. Psychiatry 2008, 193:389-394.
18. Montgomery S.A., et al. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J. Clin. Psychiatry 2006, 67:771-782.
19. Müller W.E., et al. Neuropharmacology of the anxiolytic drug opipramol, a sigma site ligand. Pharmacopsychiatry 2004, 37(Suppl 3):S189-197.
20. Pande A.C., et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am. J. Psychiatry 2003, 160:533-540.
21. Pohl R.B., et al. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J. Clin. Psychopharmacol. 2005, 25:151-158.
22. Rickels K., et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch. Gen. Psychiatry 2005, 62:1022-1030.
23. Rickels K., et al. Nefazodone and imipramine in major depression: a placebo-controlled trial. Br. J. Psychiatry 1994, 164:802-805.
24. Rickels K., et al. Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment. Int. Clin. Psychopharmacol 2012, 27:142-150.
25. Rutherford B.R., Sneed J.R., Roose S.P. Does study design influence outcome?. The effects of placebo control and treatment duration in antidepressant trials. Psychother. Psychosom. 2009, 78:172-181.
26. Snaith R.P. The Hospital Anxiety and Depression Scale. Health Qual. Life Outcomes 2003, 1:29.
27. Treweek S., Zwarenstein M. Making trials matter: pragmatic and explanatory trials and the problem of applicability. Trials 2009, 10:37.
28. Tunis S.R., Stryer D.B., Clancy C.M. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003, 290:1624-1632.
29. Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 1983, 67:361-370.